-
公开(公告)号：EP1509251B1
公开(公告)日：2008-02-27
申请号：EP03728710.9
申请日：2003-05-07
发明人： TAYLOR, Catherine , WANG, Tzann-Wei , PETROV, Larry , CARLSON, John, C. , NARAYANSINGH, Richard , THOMPSON, John, E. , CLICHE, Dominic , KAUP, Marianne
CPC分类号： C12N15/1136 , C07K14/4747 , C12N9/0004 , C12N15/1137 , C12Q1/6876 , C12Q2600/158
摘要： The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
-
2.发明公开USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF EIF-5A1 有权的siRNA裁撤表达EIF-5A1作者：USE IN治疗青光眼
公开(公告)号：EP1601767A2
公开(公告)日：2005-12-07
申请号：EP04717933.8
申请日：2004-03-05
发明人： THOMPSON, John, E. , TAYLOR, Catherine , CLICHE, Dominic , HEIKKILA, Elisabeth, M.,c/o university Waterloo , SENCHYNA, Diana,M,c/o University of Waterloo , FLANAGAN, John, G,c/o University of Waterloo
IPC分类号： C12N15/11 , A61K31/713 , A61P27/00 , A61P37/00
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
-
公开(公告)号：EP1578452A2
公开(公告)日：2005-09-28
申请号：EP03809607.9
申请日：2003-10-22
发明人： THOMPSON, John, E. , TAYLOR, Catherine , CLICHE, Dominic , DINARELLO, Charles , REZNIKOV, Leonid , POMERANTZ, Benjamin
CPC分类号： C07K14/4747 , C12Q1/6883 , C12Q2600/158
摘要： The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.
-
4.发明授权USE OF siRNA TO SUPPRESS EXPRESSION OF EIF-5A1 IN THE TREATMENT OF GLAUCOMA 有权的siRNA裁撤表达EIF-5A1作者：USE IN治疗青光眼
公开(公告)号：EP1601767B1
公开(公告)日：2012-04-25
申请号：EP04717933.8
申请日：2004-03-05
发明人： THOMPSON, John, E. , TAYLOR, Catherine , CLICHE, Dominic , HEIKKILA, Elisabeth, M. , SENCHYNA, Diana Michelle , FLANAGAN, John Gerard
IPC分类号： C12N15/113 , A61K31/713 , A61P27/06
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12N2310/53
摘要： The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
-
公开(公告)号：EP1578452B1
公开(公告)日：2008-01-23
申请号：EP03809607.9
申请日：2003-10-22
发明人： THOMPSON, John, E. , TAYLOR, Catherine , CLICHE, Dominic , DINARELLO, Charles , REZNIKOV, Leonid , POMERANTZ, Benjamin
CPC分类号： C07K14/4747 , C12Q1/6883 , C12Q2600/158
摘要： The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.
-
公开(公告)号：EP1509251A2
公开(公告)日：2005-03-02
申请号：EP03728710.9
申请日：2003-05-07
发明人： TAYLOR, Catherine , WANG, Tzann-Wei , PETROV, Larry , CARLSON, John, C. , NARAYANSINGH, Richard , THOMPSON, John, E. , CLICHE, Dominic , KAUP, Marianne
IPC分类号： A61K48/00
CPC分类号： C12N15/1136 , C07K14/4747 , C12N9/0004 , C12N15/1137 , C12Q1/6876 , C12Q2600/158
摘要： The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
